Powered by bioaccess®
Global Trial Accelerators™
Global Trial Accelerators™
Fast-Tracking First-in-Human Trials, Anywhere Hosted by bioaccess® CEO, Julio G. Martínez-Clark, the Global Trial Accelerators™ podcast (formerly known as LATAM Medtech Leaders) delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia. What You’ll Learn: Speed Secrets: How to secure ethics approval in 4–6 weeks (vs. 6+ months in US/EU) using harmonized pathways like MINSA (Panama), ALIMS (Serbia), and Australia’s CTN. Cost-to-Speed Hacks: Operational strategies to reduce trial budgets by 30% while maintaining FDA/EMA compliance. Global Patient Access: Leverage treatment-naive populations in cardiology, rare diseases, and advanced therapies across 50+ pre-vetted sites. Why Listen? Actionable Playbooks: Reverse-engineer success stories from startups that enrolled cohorts 50% faster and secured Series B funding 12–18 months early. Regulatory Intel: Stay ahead of shifting guidelines in LATAM, Eastern Europe, and APAC with on-the-ground experts. Future-Proof Insights: Explore decentralized trials, AI-driven recruitment, and post-trial commercialization in $1B+ markets. “bioaccess®’s Serbia site activated in 8 weeks-9 months faster than our EU delay. This podcast is why we partnered with them.” – Digital Health Startup CEO New episodes drop weekly. Subscribe to unlock your shortcut to global trial velocity. Brought to you by bioaccess® – Turning “anywhere” into accelerated FDA/EMA submissions since 2010.
Choose your favorite podcast player
Over 30,000 LinkedIn followers!

Fast-Tracking First-in-Human Trials, Anywhere

The Global Trial Accelerators™ podcast (formerly known as LATAM Medtech Leaders) delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia.

Recent

Sept. 26, 2025

Nicholas Kadysh, CEO at PharmAla Biotech

In this episode, we sit down with Nicholas Kadysh, CEO of PharmAla Biotech, the company pioneering GMP MDMA production and recognized as the top-performing stock on the Canadian capital markets in 2023 by The Market Herald. As Chair of Psychedelics Canada, Nicholas has played a pivotal role in str…

Watch the Video
Sept. 26, 2025

Nicholas Kadysh, CEO at PharmAla Biotech

In this episode, we welcome Nicholas Kadysh , CEO of PharmAla Biotech , the company pioneering GMP MDMA production and named the top-performing stock on the Canadian capital markets in 2023 by The Market Herald . As Chair of ...

Listen to the Episode
Sept. 18, 2025

Carolina Alarco, Founder & Principal, Bio Strategy Advisors

Carolina is a senior biotech executive with over 25 years of experience in the biopharmaceutical industry. She is the Founder & Principal of Bio Strategy Advisors, a strategic consulting firm specializing in start-up formation, corporate strategy, strategic partnerships, and global expansion. She …

Watch the Video
Sept. 18, 2025

Carolina Alarco, Founder & Principal, Bio Strategy Advisors

In this episode, we sit down with Carolina Alarco, a senior biotech executive with over 25 years of experience in the biopharmaceutical industry. Carolina is the Founder & Principal of Bio Strategy Advisors, serves on multiple biotech and nonprofit boards, and is the Co-Founder & Co-Chair of Latino…

Listen to the Episode
Sept. 11, 2025

Jason Hurt, Founder & CEO of Theragnostic Insights

In this episode, we welcome Dr. Jason Hurt, a clinician-scientist and entrepreneur with deep expertise in radiopharmaceutical development, clinical trial strategy, and oncology drug development. Dr. Hurt is the founder of Theragnostic Insights, a consulting and strategic advisory firm launched i…

Watch the Video
Sept. 11, 2025

Jason Hurt, Founder & CEO of Theragnostic Insights

In this episode, we are joined by Dr. Jason Hurt, a clinician-scientist and entrepreneur with extensive experience in radiopharmaceutical development, clinical trial strategy, and oncology drug development.  In March 2025, Dr. Hurt founded Theragnostic Insights, a consulting and strategic adviso…

Listen to the Episode

Recent Blog Posts

Sept. 24, 2025

Navigating the Complexities of Biotech Strategy: Key Insights from Ca…

Welcome to the blog, where we delve deeper into the fascinating topics covered on our podcast. Today, we're unpacking the intricate world of biotech strategy, drawing on the insightful conversation we had with Carolina Alarco, Founder & Principa…

Read the Blog Post
Sept. 17, 2025

The Power of Theranostics: Transforming Healthcare with Targeted Trea…

Welcome to the blog! This post expands on the fascinating topic we explored in our latest podcast episode, "Jason Hurt, Founder & CEO of Theragnostic Insights." In this episode, we delved into the revolutionary field of theranostics with Jason H…

Read the Blog Post
Sept. 15, 2025

Heligenics: Revolutionizing Healthcare with Personalized Diagnostics

In our latest episode, we had the distinct pleasure of speaking with Martin Schiller, the Founder and CEO of Heligenics Inc., a company poised to reshape the landscape of healthcare through personalized diagnostics. This blog post delves deeper into…

Read the Blog Post

About the Host

Julio G Martinez-Clark Profile Photo

Julio G Martinez-Clark

CEO, bioaccess®

Julio G. Martinez-Clark, CEO of bioaccess®, has spent over a decade dismantling barriers to Medtech, Biopharma, and Radiopharma innovation by positioning Latin America, Eastern Europe (the Balkans), and Australia as global leaders in clinical research. His work challenges entrenched perceptions of the region, transforms healthcare access for underserved populations, and reimagines how medical innovations reach commercialization. Through bioaccess®, Julio has created a blueprint for cost-effective, ethically rigorous clinical trials that accelerate time-to-market while elevating local communities.